TW200924777A - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
TW200924777A
TW200924777A TW097135270A TW97135270A TW200924777A TW 200924777 A TW200924777 A TW 200924777A TW 097135270 A TW097135270 A TW 097135270A TW 97135270 A TW97135270 A TW 97135270A TW 200924777 A TW200924777 A TW 200924777A
Authority
TW
Taiwan
Prior art keywords
alkyl
group
aryl
heteroaryl
hydrocarbyl
Prior art date
Application number
TW097135270A
Other languages
English (en)
Chinese (zh)
Inventor
Zuomei Li
Koji Murakami
Original Assignee
Methylgene Inc
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc, Taiho Pharmaceutical Co Ltd filed Critical Methylgene Inc
Publication of TW200924777A publication Critical patent/TW200924777A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW097135270A 2007-09-14 2008-09-12 Combination therapy TW200924777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97235307P 2007-09-14 2007-09-14
US4395708P 2008-04-10 2008-04-10

Publications (1)

Publication Number Publication Date
TW200924777A true TW200924777A (en) 2009-06-16

Family

ID=40451522

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097135270A TW200924777A (en) 2007-09-14 2008-09-12 Combination therapy

Country Status (6)

Country Link
US (1) US20090124631A1 (enExample)
JP (1) JP2010539104A (enExample)
KR (1) KR20100072024A (enExample)
CN (1) CN101861151B (enExample)
TW (1) TW200924777A (enExample)
WO (1) WO2009033281A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
JP6295081B2 (ja) * 2011-02-24 2018-03-14 バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012118782A1 (en) 2011-02-28 2012-09-07 Repligen Corporation Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
ES2627010T3 (es) 2012-07-19 2017-07-26 Janssen Pharmaceutica, N.V. Antagonistas de octahidro-ciclopentapirrolilo de CCR2
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP2968565A2 (en) * 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
RU2665554C2 (ru) 2013-03-15 2018-08-31 Байомарин Фармасьютикал Инк. Ингибиторы hdac
CN107205988A (zh) 2014-07-07 2017-09-26 埃斯泰隆制药公司 利用组蛋白脱乙酰酶抑制剂治疗白血病
CA2970500C (en) 2014-12-12 2023-08-29 Acetylon Pharmaceuticals, Inc. Piperidine derivatives as hdac1/2 inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3043618A1 (en) * 2016-11-23 2018-05-31 Regenacy Pharmaceuticals, Llc Piperazine derivatives as selective hdac1,2 inhibitors
US10507250B2 (en) * 2017-09-08 2019-12-17 Institute Of Nuclear Energy Research, Atomic Energy Council, Executive Yuan Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
CA3113819A1 (en) * 2018-10-10 2020-04-16 Regenacy Pharmaceuticals, Llc Pyrimidine and pyrazine hdac1,2 inhibitors
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20240374569A1 (en) * 2021-09-22 2024-11-14 Henry Ford Health System Hdac3 inhibitors for the treatment of langerhans cell histiocytosis and langerhans cell sarcoma
CA3240229A1 (en) 2021-12-03 2023-06-08 Tango Therapeutics, Inc. Novel hdac inhibitors and therapeutic use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
AU2005225471B2 (en) * 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase

Also Published As

Publication number Publication date
KR20100072024A (ko) 2010-06-29
JP2010539104A (ja) 2010-12-16
US20090124631A1 (en) 2009-05-14
CN101861151A (zh) 2010-10-13
CN101861151B (zh) 2014-08-13
WO2009033281A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
CN101861151B (zh) 使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗
Mo et al. Human ABCG2: structure, function, and its role in multidrug resistance
TWI283676B (en) Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
KR102427777B1 (ko) 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
ES2882223T3 (es) 17Alfa-valerato de cortexolona para el uso en el tratamiento de tumores
EP2818170B1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridin yl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
BR112019025346A2 (pt) uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
JP2017505787A (ja) 治療薬としてのヒトアンドロゲン受容体dna結合ドメイン(dbd)化合物およびそれらを使用する方法
CN107531683B (zh) Usp7抑制剂化合物及使用方法
EP3697767B1 (en) Compounds and methods for treating cancer
US20220062291A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) with reduced inhibitory activity targeted to the dopamine d2 receptor and accompanying toxicity
JP2018108998A (ja) Pi−3キナーゼ阻害剤の投与レジメン
Costantino et al. Dehydroleucodine inhibits tumor growth in a preclinical melanoma model by inducing cell cycle arrest, senescence and apoptosis
Cui et al. Pyrvinium sensitizes clear cell renal cell carcinoma response to chemotherapy via casein kinase 1α-dependent inhibition of Wnt/β-catenin
WO2012112567A1 (en) Small molecule inhibitors of agbl2
EP3871665B1 (en) Inhibitors of rna-binding proteins as anti-cancer drugs
WO2021046178A1 (en) Compounds and methods for treating cancer
KR101599259B1 (ko) 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물
BR112020008325A2 (pt) terapias de combinação com o inibidor de ezh2
HK1149213A (en) Cancer combination therapy with a selective inhibitor of histone deacetylase hdac1, hdac2 and/or hdac3 and a microtubule stabilizer
JP2006348021A (ja) 細胞周期阻害剤
KR101078091B1 (ko) 코르다 필럼(Chorda Filum) 추출물을 유효 성분으로 포함하는 암의 예방 및 치료용 조성물
WO2021046220A1 (en) Compounds and methods for treating cancer
WO2021257696A1 (en) Isoform-specific aldehyde dehydrogenase inhibitors
KR20080086027A (ko) 고형암 세포에서 사이클로필린 a의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법